Media Briefing: FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

** FOR CREDENTIALED MEDIA ONLY **

WHAT:

A media briefing to discuss the FDA's announcement that it is requesting manufacturers withdraw all prescription and over-the-counter ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac).

WHO:

Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research

WHEN:

Wednesday, April 1, at 1:15 p.m. ET

HOW:

Callers may dial toll-free at 888-790-1783 or 1-212-287-1652. The passcode for all callers is "FDA." A replay will be available beginning one hour after the briefing until May 1, 2020. To listen to the replay, call toll-free at 866-350-3614 or 1-203-369-0039.

Media Contact: Sarah Peddicord, Sarah.Peddicord@fda.hhs.gov, 301-796-2805
Consumer Inquiries: Email, 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

/PRNewswire -- April 1, 2020/

SOURCE U.S. Food and Drug Administration